A new rating scale for Alzheimer's disease Am J Psychiatry 141: 1356-1364

American Journal of Psychiatry (Impact Factor: 12.3). 12/1984; 141(11):1356-64. DOI: 10.1176/ajp.141.11.1356
Source: PubMed


A new rating instrument, the Alzheimer's Disease Assessment Scale, was designed specifically to evaluate the severity of cognitive and noncognitive behavioral dysfunctions characteristic of persons with Alzheimer's disease. Item descriptions, administration procedures, and scoring are outlined. Twenty-seven subjects with Alzheimer's disease and 28 normal elderly subjects were rated on 40 items. Twenty-one items with significant intraclass correlation coefficients for interrater reliability (range, .650-.989) and significant Spearman rank-order correlation coefficients for test-retest reliability (range, .514-1) constitute the final scale. Subjects with Alzheimer's disease had significantly more cognitive and noncognitive dysfunction than the normal elderly subjects.

Download full-text


Available from: Richard C Mohs, Aug 20, 2014
  • Source
    • "The MMSE was used to evaluate cognitive impairment in the AD patients. The MMSE was assessed twice: before DNP treatment and after treatment with DNP for at least 3 months [20]. Blood samples were collected from the patients. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Aim: Polymorphisms in the apolipoprotein E and CYP2D6 genes are widely reported to be related to Alzheimer's disease. However, few studies have focused on the relationship between polymorphisms in apolipoprotein E and CYP2D6 (rs1065852) genes and therapeutic responses to donepezil (DNP). This study explored the influence of apolipoprotein E3 and CYP2D6 (rs1065852) gene polymorphisms on therapeutic responses to donepezil in Han Chinese patients with Alzheimer's disease. Materials and methods: A total of 85 patients with mild to moderate Alzheimer's disease who were treated with 2.5-10mg of DNP per day for at least 3 months were enrolled. Mini-Mental State Examination scores were measured before and after DNP treatment, and the apolipoprotein E3 and CYP2D6 (rs1065852) genotypes of the patients were determined. Results: We found that ApoE E3 non-carriers responded better to DNP treatment than E3 carriers (p=0.000) and that CYP2D6*10/*10 patients (MMSE score change: 0.29±3.27) exhibited better therapeutic responses to DNP than did CYP2D6*1/*1 and CYP2D6*1/*10 patients (p=0.033). Patients who were ApoE E3 non-carriers and who had the CYP2D6*10/*10 genotype exhibited a trend toward better clinical responses to DNP therapy. Conclusions: The ApoE E3 allele and the CYP2D6 rs1065852 polymorphism may provide clinically relevant information for predicting therapeutic responses to DNP therapy.
    Full-text · Article · Feb 2016 · Neuroscience Letters
  • Source
    • "Moderately severe to severe dementia was measured according to current guidelines (Vellas et al., 2005) (MMSE lower than 15 or stages 5 to 6 of the GDS). The secondary outcomes measured at 3 and 24 months included: institutionalization, cognitive deterioration (ADAScog ) (Rosen et al., 1984), behavioral symptoms (Neuropsychiatric Inventory; NPI) (Cummings et al., 1994), functional abilities (Disablement Assessment for Dementia; DAD (Gélinas et al., 1999 "
    [Show abstract] [Hide abstract]
    ABSTRACT: Background: Although non-drug interventions are widely used in patients with Alzheimer's disease, few large scale randomized trials involving a long-term intervention and several cognitive-oriented approaches have been carried out. ETNA3 trial compares the effect of cognitive training, reminiscence therapy, and an individualized cognitive rehabilitation program in Alzheimer's disease to usual care. Methods: This is a multicenter (40 French clinical sites) randomized, parallel-group trial, with a two-year follow-up comparing groups receiving standardized programs of cognitive training (group sessions), reminiscence therapy (group sessions), individualized cognitive rehabilitation program (individual sessions), and usual care (reference group). Six hundred fifty-three outpatients with Alzheimer's disease were recruited. The primary efficacy outcome was the rate of survival without moderately severe to severe dementia at two years. Secondary outcomes were cognitive impairment, functional disability, behavioral disturbance, apathy, quality of life, depression, caregiver's burden, and resource utilization. Results: No impact on the primary efficacy measure was evidenced. For the two group interventions (i.e. cognitive training and reminiscence), none of the secondary outcomes differed from usual care. The larger effect was seen with individualized cognitive rehabilitation in which significantly lower functional disability and a six-month delay in institutionalization at two years were evidenced. Conclusions: These findings challenge current management practices of Alzheimer's patients. While cognitive-oriented group therapies have gained popularity, this trial does not show improvement for the patients. The individualized cognitive rehabilitation intervention provided clinically significant results. Individual interventions should be considered to delay institutionalization in Alzheimer's disease.
    Full-text · Article · Nov 2015 · International Psychogeriatrics
  • Source
    • "Figure adapted with permission from Kuhn et al. (2015) The rationale for deep brain stimulation in Alzheimer's disease OFF followed by 2 weeks ON), then an 11 months followup open label period (Kuhn et al. 2015). The primary outcome measure was change in Alzheimer's disease assessment scale–cognitive subscale (ADAS-Cog) (Rosen et al. 1984), which worsened by an average of three points over 1 year, representing a non-significant change. Four of six patients were considered responders based on a stable or improved ADAS-Cog score at 1 year. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Alzheimer’s disease is a major worldwide health problem with no effective therapy. Deep brain stimulation (DBS) has emerged as a useful therapy for certain movement disorders and is increasingly being investigated for treatment of other neural circuit disorders. Here we review the rationale for investigating DBS as a therapy for Alzheimer’s disease. Phase I clinical trials of DBS targeting memory circuits in Alzheimer’s disease patients have shown promising results in clinical assessments of cognitive function, neurophysiological tests of cortical glucose metabolism, and neuroanatomical volumetric measurements showing reduced rates of atrophy. These findings have been supported by animal studies, where electrical stimulation of multiple nodes within the memory circuit have shown neuroplasticity through stimulation-enhanced hippocampal neurogenesis and improved performance in memory tasks. The precise mechanisms by which DBS may enhance memory and cognitive functions in Alzheimer’s disease patients and the degree of its clinical efficacy continue to be examined in ongoing clinical trials.
    Full-text · Article · Oct 2015 · Journal of Neural Transmission
Show more